They spend billions on drugs that never make it to market so I don’t know why it’s seen as bad when a drug company goes all in on something that does work. Blame the FDA for allowing separate patents on racemic mixtures and pure enantiomers. I’m pretty sure that going forward they’re not allowing this with new drugs.
Also, I don’t think omeprazole is an H1 blocker at all. May want to correct that section.
Shoot, you're correct. I was writing about the second generation antihistamines and got mixed up.
Anyways, I don't think just because pharma can means that it should. The FDA shouldn't have allowed it, but I see what AstraZeneca did as not much more than robbing patients/insurance. Developing drugs is hard and expensive, but that doesn't justify these sorts of shenanigans.
There’s probably an obnoxious argument to be made that as a publicly traded company they have a fiduciary duty to screw the insurance companies and the general public. Not that it should be that way.
They spend billions on drugs that never make it to market so I don’t know why it’s seen as bad when a drug company goes all in on something that does work. Blame the FDA for allowing separate patents on racemic mixtures and pure enantiomers. I’m pretty sure that going forward they’re not allowing this with new drugs.
Also, I don’t think omeprazole is an H1 blocker at all. May want to correct that section.
Shoot, you're correct. I was writing about the second generation antihistamines and got mixed up.
Anyways, I don't think just because pharma can means that it should. The FDA shouldn't have allowed it, but I see what AstraZeneca did as not much more than robbing patients/insurance. Developing drugs is hard and expensive, but that doesn't justify these sorts of shenanigans.
There’s probably an obnoxious argument to be made that as a publicly traded company they have a fiduciary duty to screw the insurance companies and the general public. Not that it should be that way.